Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
Universe Pharmaceuticals INC
Conservative balance sheet (liabilities/equity 0.23x); but revenue fell -22.4% YoY.
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
Universe Pharmaceuticals INC shows $17.9B in FY2025 revenue (-22.4% YoY), a -20.6% net margin, and -6.5% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001809616, latest 4 filed 2026-05-21) · EODHD · rules-based read · as of 6/18/2026, 12:09:55 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $48.0M | $40.1M | $32.3B | $23.0B | $17.9B |
| Gross profit | $25.3M | $21.9M | $10.3B | $6.07B | $6.30B |
| Operating income | $13.6M | -$7.02M | -$3.97B | -$8.02B | -$2.92B |
| Net income | $11.3M | -$7.91M | -$6.58B | -$8.73B | -$3.67B |
| Diluted EPS | $3.58 | -$1,309.11 | -$1,089.21 | -$626.96 | -$8.06 |
| Net margin | 23.6% | -19.7% | -20.4% | -37.9% | -20.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median
| 2026-05-07 | Lai Gang Chief Executive Officer | Award | 71.9K | |
| 2026-05-07 | Lai Gang Chief Executive Officer | Award | 12.6K |